

3. Lonsurf, Efficacy overall survival data, [Internet], [cited 2/2019]. Available from: <https://www.lonsurfhcp.com/mcrrc-treatment/efficacy>.

4. Souhrn údajů o přípravku, SPC [Internet], [cited 10. 12. 2020]. Available from: https://labeling.bayerhealthcare.com/html/products/pi/Stivarga_PI.pdf.

5. ClinicalTrials NCT01103323, Regorafenib [Internet] 2015, [cited 24.6.2015]. Available from: <https://clinicaltrials.gov/ct2/show/NCT01103323>.

6. Obermannova S, Grell P, Dvorak J, et al. TAS-102 in metastatic colorectal cancer (mCRC) – predictive and prognostic factors in a European patient population. Japanese Society of Medical Oncology (JSMO). Annual meeting; 2018. Abstract P2-088.

7. Kopečková K, Buchler T, Bortlíček Z, et al. Regorafenib in the real-life clinical practice: data from Czech Registry. Target Oncol. 2017;12:89-95.

8. Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl

J Med. 2015;372(20):1909-1919.

9. Taberero J, Taieb J, Prager G, et al. Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design. Future Oncol. 2021;17(16):1977-1985. Available from: <https://www.futuremedicine.com/doi/full/10.2217/fon-2020-1238>. Last accessed: January 2023.

10. Prager GW, Taieb J, Fakih M, et al. Trifluridine–tipiracil and bevacizumab in refractory metastatic colorectal cancer. New England Journal of Medicine. 2023;388(18):1657-1667.

11. Napolitano S, De Falco V, Martini G, et al. Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2023; online May 18. doi:10.1001/jamaoncol.2023.0655.

12. Sartore-Bianchi A, Pietrantonio F, Lonardi S, et al. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial. Nat Med. 2022 Aug;28(8):1612-1618. doi: 10.1038/

s41591-022-01886-0. Epub 2022 Aug 1. PMID: 35915157; PMCID: PMC9386661.

13. Li J, Qin S, Xu RH, Shen L, et al. Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. JAMA. 2018;319(24):2486.

14. Xu X, Yu Y, Liu M, et al. Efficacy and safety of regorafenib and fruquintinib as third-line treatment for colorectal cancer: a narrative review. Transl Cancer Res. 2022;11(1):276-287. doi: 10.21037/tcr-20-3539. PMID: 35261903; PMCID: PMC8841594.

15. Strickler JH, Cercek A, Siena S, et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. The Lancet Oncology. 2023;24(5):496-508.

16. Takayuki Y, et al. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer. Nature Communications. 2023;14(1):3332.

VZDĚLÁVEJTE SE ON-LINE a získejte kredity

- získejte 2–12 kreditů za kurz
- vyberte si z různých medicínských specializací
- vzdělávejte se dle svých časových možností

SOLEN
MEDICAL EDUCATION



www.solen.cz



On-line
vzdělávání